TITLE:
Effect of Integrated Traditional Chinese and Western Medicine Based on Syndrome Differentiation on Neurological Outcome and Safety in Patients with Acute Ischemic Stroke Due to Large Vessel Occlusion after Endovascular Treatment: A Prospective Randomized Controlled Trial
AUTHORS:
Xiangrui Gong, Tianya Wu, Long Ai, Feng Ding, Gang Yang
KEYWORDS:
Acute Ischemic Stroke, Large Vessel Occlusion, Endovascular Treatment, Integrative Medicine, Syndrome Differentiation, Randomized Controlled Trial
JOURNAL NAME:
Journal of Biosciences and Medicines,
Vol.14 No.11,
November
16,
2026
ABSTRACT: Background and Purpose: Despite successful endovascular treatment (EVT) in acute ischemic stroke due to large vessel occlusion (AIS-LVO), the rate of futile recanalization remains high. This study aimed to evaluate the effect of integrated traditional Chinese and Western medicine (ITCWM) based on syndrome differentiation on neurological recovery and safety in AIS-LVO patients after EVT. Methods: This was a prospective, single-center, randomized controlled trial. A total of 200 AIS-LVO patients with successful recanalization (modified Thrombolysis in Cerebral Infarction [mTICI] ≥ 2b) were enrolled and randomly assigned 1:1 to either the treatment group or the control group (n = 100 per group). Both groups received standard post-EVT management, including antiplatelet therapy, statins, blood pressure and glucose control, and early rehabilitation. The treatment group additionally received individualized Chinese herbal decoctions or proprietary Chinese medicines according to seven TCM syndrome differentiations starting 24 - 72 h post-EVT. The primary outcomes were the National Institutes of Health Stroke Scale (NIHSS) score at 14 days post-treatment and the shift in NIHSS score (ΔNIHSS = baseline - 14-day score). The secondary outcome was good functional outcome (modified Rankin Scale [mRS] ≤ 2) at 90 days. Safety outcomes included symptomatic intracranial hemorrhage (sICH), mortality, and adverse drug reactions. Results: Baseline characteristics, including age, sex, baseline NIHSS, and ASPECTS, were comparable between groups (all P > 0.05). At 14 days, both groups showed significant reductions in NIHSS scores compared with baseline (both P 0.05). No significant differences were observed in the incidence of sICH (4.0% vs. 10.0%, P > 0.05), mortality (5.0% vs. 6.0%, P > 0.05), or hepatic/renal dysfunction (6.0% vs. 3.0%, P > 0.05). Conclusions: Adjunctive TCM treatment based on syndrome differentiation did not increase safety risks but failed to demonstrate statistically significant superiority over standard Western medicine alone in improving NIHSS scores or 90-day functional outcomes. A trend toward greater neurological improvement was observed in the ITCWM group, warranting further investigation in larger, multicenter trials.